Potential Impact of Prescribing Metformin According to eGFR Rather Than Serum Creatinine | Zendy

Delphine S. Tuot | Zendy; Feng Lin | Zendy; Michael G. Shlipak | Zendy; Vanessa Grubbs | Zendy; Chiyuan Hsu | Zendy; Jerry Yee | Zendy; Vahakn B. Shahinian | Zendy; Rajiv Saran | Zendy; Sharon Saydah | Zendy; Desmond E. Williams | Zendy; Neil R. Powe | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Potential Impact of Prescribing Metformin According to eGFR Rather Than Serum Creatinine

Author(s) -

Delphine S. Tuot,

Feng Lin,

Michael G. Shlipak,

Vanessa Grubbs,

Chiyuan Hsu,

Jerry Yee,

Vahakn B. Shahinian,

Rajiv Saran,

Sharon Saydah,

Desmond E. Williams,

Neil R. Powe

Publication year - 2015

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc15-0542

Subject(s) - medicine , renal function , metformin , creatinine , diabetes mellitus , kidney disease , logistic regression , population , odds ratio , urology , cystatin c , endocrinology , environmental health

Many societies recommend using estimated glomerular filtration rate (eGFR) rather than serum creatinine (sCr) to determine metformin eligibility. We examined the potential impact of these recommendations on metformin eligibility among U.S. adults.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research